Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Cytokeratin and protein expression patterns in squamous cell carcinoma of the oral cavity provide evidence for two distinct pathogenetic pathways.

Frohwitter G, Buerger H, VAN Diest PJ, Korsching E, Kleinheinz J, Fillies T.

Oncol Lett. 2016 Jul;12(1):107-113.

2.

The soluble form of BMPRIB is a novel therapeutic candidate for treating bone related disorders.

Yamawaki K, Kondo Y, Okada T, Oshima T, Kakitani M, Tomizuka K.

Sci Rep. 2016 Jan 6;6:18849. doi: 10.1038/srep18849.

3.

MicroRNA variants as genetic determinants of bone mass.

Dole NS, Delany AM.

Bone. 2016 Mar;84:57-68. doi: 10.1016/j.bone.2015.12.016. Review.

4.

Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy.

Dai K, Qin F, Zhang H, Liu X, Guo C, Zhang M, Gu F, Fu L, Ma Y.

Oncotarget. 2016 Jan 26;7(4):4770-84. doi: 10.18632/oncotarget.6613.

5.

Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response.

Chapellier M, Bachelard-Cascales E, Schmidt X, Clément F, Treilleux I, Delay E, Jammot A, Ménétrier-Caux C, Pochon G, Besançon R, Voeltzel T, Caron de Fromentel C, Caux C, Blay JY, Iggo R, Maguer-Satta V.

Stem Cell Reports. 2015 Feb 10;4(2):239-54. doi: 10.1016/j.stemcr.2014.12.007.

6.

The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells.

Gatza CE, Elderbroom JL, Oh SY, Starr MD, Nixon AB, Blobe GC.

Neoplasia. 2014 Jun;16(6):489-500. doi: 10.1016/j.neo.2014.05.008.

7.

ΔNp63α-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells.

Balboni AL, Hutchinson JA, DeCastro AJ, Cherukuri P, Liby K, Sporn MB, Schwartz GN, Wells WA, Sempere LF, Yu PB, DiRenzo J.

Cancer Res. 2013 Jan 15;73(2):1020-30. doi: 10.1158/0008-5472.CAN-12-2862.

8.

Genetic variation in bone morphogenetic proteins and breast cancer risk in hispanic and non-hispanic white women: The breast cancer health disparities study.

Slattery ML, John EM, Torres-Mejia G, Herrick JS, Giuliano AR, Baumgartner KB, Hines LM, Wolff RK.

Int J Cancer. 2013 Jun 15;132(12):2928-39. doi: 10.1002/ijc.27960.

9.

BMPR2 expression is suppressed by signaling through the estrogen receptor.

Austin ED, Hamid R, Hemnes AR, Loyd JE, Blackwell T, Yu C, Phillips Iii JA, Gaddipati R, Gladson S, Gu E, West J, Lane KB.

Biol Sex Differ. 2012 Feb 20;3(1):6. doi: 10.1186/2042-6410-3-6.

10.

Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics.

Haupt A, Joberty G, Bantscheff M, Fröhlich H, Stehr H, Schweiger MR, Fischer A, Kerick M, Boerno ST, Dahl A, Lappe M, Lehrach H, Gonzalez C, Drewes G, Lange BM.

BMC Cancer. 2012 Jan 25;12:38. doi: 10.1186/1471-2407-12-38.

11.

Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators.

Owens P, Pickup MW, Novitskiy SV, Chytil A, Gorska AE, Aakre ME, West J, Moses HL.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2814-9. doi: 10.1073/pnas.1101139108.

12.

Diverse bone morphogenetic protein expression profiles and smad pathway activation in different phenotypes of experimental canine mammary tumors.

Wensman H, Heldin NE, Pejler G, Hellmén E.

PLoS One. 2009 Sep 22;4(9):e7133. doi: 10.1371/journal.pone.0007133.

13.

A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis.

Saetrom P, Biesinger J, Li SM, Smith D, Thomas LF, Majzoub K, Rivas GE, Alluin J, Rossi JJ, Krontiris TG, Weitzel J, Daly MB, Benson AB, Kirkwood JM, O'Dwyer PJ, Sutphen R, Stewart JA, Johnson D, Larson GP.

Cancer Res. 2009 Sep 15;69(18):7459-65. doi: 10.1158/0008-5472.CAN-09-1201.

14.

GAGE: generally applicable gene set enrichment for pathway analysis.

Luo W, Friedman MS, Shedden K, Hankenson KD, Woolf PJ.

BMC Bioinformatics. 2009 May 27;10:161. doi: 10.1186/1471-2105-10-161.

15.

Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease.

Helms MW, Kemming D, Pospisil H, Vogt U, Buerger H, Korsching E, Liedtke C, Schlotter CM, Wang A, Chan SY, Brandt BH.

Br J Cancer. 2008 Sep 2;99(5):774-80. doi: 10.1038/sj.bjc.6604556.

16.

Aggressive melanoma cells escape from BMP7-mediated autocrine growth inhibition through coordinated Noggin upregulation.

Hsu MY, Rovinsky SA, Lai CY, Qasem S, Liu X, How J, Engelhardt JF, Murphy GF.

Lab Invest. 2008 Aug;88(8):842-55. doi: 10.1038/labinvest.2008.55.

17.

Induction of Smad1 by MT1-MMP contributes to tumor growth.

Freudenberg JA, Chen WT.

Int J Cancer. 2007 Sep 1;121(5):966-77.

18.

Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer.

van der Groep P, Hoelzel M, Buerger H, Joenje H, de Winter JP, van Diest PJ.

Breast Cancer Res Treat. 2008 Jan;107(1):41-7.

19.

Genome-wide approaches for identification of nuclear receptor target genes.

Tavera-Mendoza LE, Mader S, White JH.

Nucl Recept Signal. 2006;4:e018.

Supplemental Content

Support Center